Please assess the completion status of the following clinical trial:

Trial Title: Protective Effect of EPA on Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants had a total cholesterol level of ≧250mg/dL(6.5m mol/L) at baseline.~* Hyperlipidemic patients with serum total cholesterol of 250mg/dL or more. (Measurement of serum total cholesterol)~* Serum total cholesterol should be measured twice at interval of 2-4weeks. A single measurement is acceptable if the cholesterol is measured by blood collection at fasting under strict compliance with dietary advice after withdrawal of the antihyperlipemic drug.~* (Wash Out) The wash out period of 4weeks (8 weeks for probucol) is necessary in patients under treatment with antihyperlipemic drug. However, if treatment with the antihyperlipemic drug was started within 6 months of the initiation of the study, the patient can participate in the study without the washout period.~Exclusion Criteria:~* Acute myocardial infarction occurring within last 6 months~* Unstable angina pectoris~* A history or complication of serious heart disease(severe arrhythmia, heart failure, cardiac myopathy, valvular disease, congenital disease, etc.)~* Receiving cardiovascular reconstruction within last 6 months~* Cerebrovascular disorders occurring within last 6 months~* Complication of serious hepatic disease or renal disease~* Malignant tumor~* Uncontrollable diabetes~* Hyperlipidemia arising from the following disease: Nephrotic syndrome, hypothyroidism, Cushing's syndrome, secondary hyperlipidemia due to other disease~* Hyperlipidemia due to some drugs such as steroid hormone~* Hemorrhage(hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.)~* Hemorrhagic diathesis~* Hypersensitivity to the study drug formulation~* Patients intending to undergo surgery~* Patients judged to be inappropriate by the physician in charge

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).